Scienture Holdings, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 20 AUSTIN BLVD., COMMACK, NY, 11725
Mailing Address 20 AUSTIN BLVD., COMMACK, NY, 11725
Phone (800) 261 0281
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025
$9.07M
Net Income
$25.78M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 4 Insider stock transaction report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | November 18, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| 424B5 Prospectus supplement | November 7, 2025 | View on SEC |
| 8-K Current report of material events | October 30, 2025 | View on SEC |
Annual Reports
10-K March 30, 2026
- Successful FDA approval and launch of SCN-102 in 2025.
- Strategic pivot to a pure-play drug development model after exiting food tech.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.